The Efficacy and Safety of Retrovir in Patients Infected With HIV Who Are Asymptomatic (CDC Group II) or Have Persistent Generalized Lymphadenopathy (CDC Group III)
This study has been completed.
First Posted: August 31, 2001
Last Update Posted: December 9, 2005
Information provided by:
NIH AIDS Clinical Trials Information Service